I-Mab to Release 1H 2024 Financial Results on August 28, 2024
Rhea-AI Summary
I-Mab (NASDAQ: IMAB), a US-based global biotech company focused on developing immunotherapies for cancer treatment, has announced it will release its 1H 2024 financial results on August 28, 2024. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss financial results, pipeline progress, and recent business highlights for the half year ended June 30, 2024.
Investors and analysts can join the conference call via domestic (1-877-407-0784) or international (1-201-689-8560) dial-in numbers, using the Conference ID: 13747695. A webcast link is also provided. The Call me™ link will be active 15 minutes before the scheduled start time. A replay of the call will be available on the I-Mab website's Investor Relations page for 6 months.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IMAB declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET
I-Mab Conference Call and Webcast Information:
Investors and analysts are invited to join the conference call at 8:00 AM ET on August 28, 2024, via:
- Domestic Dial-in: 1-877-407-0784
- International Dial-in: 1-201-689-8560
- Conference ID: 13747695
- Webcast: please click here
Note that Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
The Call me™ link will be made active 15 minutes prior to the scheduled start time.
A webcast of the call will also be available on the I-Mab website, on the Upcoming Events section of the Investor Relations page, available by clicking here. A replay of the call will be accessible under the Past Events section of the Investor Relations page and will be archived for 6 months.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.
I-Mab has established operations in
I-Mab Contacts
Investors & Media |
Tyler Ehler |
Senior Director, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-release-1h-2024-financial-results-on-august-28-2024-302221660.html
SOURCE I-Mab Biopharma